Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Page kidney

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    42 result(s) found for: Page kidney. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2013-004934-14 Sponsor Protocol Number: EMASPK01 Start Date*: 2014-01-15
    Sponsor Name:Institut klinické a experimentální medicíny
    Full Title: EVEROLIMUS VERSUS MYCOPHENOLIC ACID IN SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANTATION TO EVALUATE THE DIFFERENCES IN RETINAL NEOVASCULARIZATION IN PATIENTS WITH DIABETIC RETINOPATHY
    Medical condition: simultaneous pancreas/kidney allograft transplantation
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004865 10048622 Pancreatic transplant LLT
    16.1 100000004865 10023438 Kidney transplant LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001516-19 Sponsor Protocol Number: 156-13-211 Start Date*: 2015-03-26
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization,
    Full Title: A Phase 3b, Multi-center, Open-label Trial to Evaluate the Long Term Safety of Titrated Immediate-release Tolvaptan (OPC 41061, 30 mg to 120 mg/day, Split dose) in Subjects with Autosomal Dominant ...
    Medical condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10036046 Polycystic kidney, autosomal dominant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed) SE (Completed) NL (Completed) BE (Completed) PL (Completed) ES (Completed) CZ (Completed) HU (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2008-003249-10 Sponsor Protocol Number: FNH-DS001 Start Date*: 2009-04-29
    Sponsor Name:University of the Saarland
    Full Title: Olmesartan, Oxidant Stress and in Vivo Re-Endothelialization Capacity of Endothelial Progenitor Cells from Patients with Chronic Kidney Disease (OECD Study)
    Medical condition: We will investigate the effect of Olmesartan Medoxomil 40 mg on the reendothelialization capacity of Endothelial Progenitor Cells in patients with chronic kidney disease. In this clinical setting O...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000334-17 Sponsor Protocol Number: TRACK_001 Start Date*: 2023-03-31
    Sponsor Name:The George Institute of Global Health
    Full Title: Treatment of cardiovascular disease with low Rivaroxaban in Advanced Chronic Kidney Disease - TRACK trial
    Medical condition: Improvement of cardiovascular outcomes in patients with advanced chronic kidney disease.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-023017-65 Sponsor Protocol Number: B1871019 Start Date*: 2011-03-17
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, CLINICAL ACTIVITY AND PHARMACOKINETICS OF BOSUTINIB (PF-05208763) VERSUS PLACEBO IN SUBJECTS WITH AUTOSOMAL...
    Medical condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004850 10036046 Polycystic kidney, autosomal dominant LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) ES (Completed) CZ (Completed) HU (Completed) GB (Completed) PL (Completed) SK (Completed) LT (Completed) IT (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000022-66 Sponsor Protocol Number: 16-HMedIdeS-12 Start Date*: 2019-03-13
    Sponsor Name:Hansa Medical AB
    Full Title: A Randomized, Open-Label, Multi-Centre, Active Control Study Investigating the Efficacy and Safety of Imlifidase in Eliminating Donor Specific Anti-HLA Antibodies in the Treatment of Active Antibod...
    Medical condition: Antibody-mediated rejection in kidney transplant patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10023439 Kidney transplant rejection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) AT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-000142-37 Sponsor Protocol Number: XM01-06 Start Date*: 2005-06-13
    Sponsor Name:BioGeneriX AG
    Full Title: Efficacy and Safety of subcutaneous administration of XM01 compared to Epoetin beta in anaemic chronic renal failure patients not yet receiving dialysis and in maintenance phase treatment with Epoe...
    Medical condition: anaemic chronic renal failure patients not yet receiving dialysis
    Disease: Version SOC Term Classification Code Term Level
    9 10009119 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2016-000187-42 Sponsor Protocol Number: 156-12-298 Start Date*: 2016-10-24
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Phase 3b, Two-part, Multicenter, One Year Randomized, Double-blind, Placebo-controlled Trial of the Safety, Pharmacokinetics, Tolerability, and Efficacy of Tolvaptan followed by a Two Year Open-l...
    Medical condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10036046 Polycystic kidney, autosomal dominant LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-004301-24 Sponsor Protocol Number: ONErgt11 Start Date*: 2012-01-05
    Sponsor Name:Free State of Bavaria, represented by the University of Regensburg, represented by Prof. Edward K. Geissler
    Full Title: The ONE Study: A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation – Reference Group Trial
    Medical condition: Kidney allograft rejection following living-donor renal transplantation.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004863 10051366 Kidney graft dysfunction LLT
    14.1 100000004870 10049581 Graft rejection episode LLT
    14.1 100000004865 10050436 Prophylaxis against renal transplant rejection LLT
    14.1 100000004863 10069030 Graft failure LLT
    14.1 100000004870 10038297 Rejection acute renal LLT
    14.1 100000004870 10021510 Immunosuppression NOS LLT
    14.1 100000004863 10038299 Rejection chronic renal LLT
    14.1 100000004870 10066543 Acute allograft rejection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-000999-15 Sponsor Protocol Number: ONEmreg12 Start Date*: 2014-02-10
    Sponsor Name:University Hospital Regensburg
    Full Title: The ONE Study: A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation - M reg Trial
    Medical condition: Kidney allograft rejection following living-donor renal transplantation.
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004863 10051366 Kidney graft dysfunction LLT
    17.0 100000004870 10049581 Graft rejection episode LLT
    17.0 100000004863 10069030 Graft failure LLT
    17.0 100000004865 10050436 Prophylaxis against renal transplant rejection LLT
    17.0 100000004870 10038297 Rejection acute renal LLT
    17.0 100000004870 10021510 Immunosuppression NOS LLT
    17.0 100000004863 10038299 Rejection chronic renal LLT
    17.0 100000004870 10066543 Acute allograft rejection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-005757-12 Sponsor Protocol Number: FAIR-HFpEF Start Date*: 2017-06-06
    Sponsor Name:Charité – Universitätsmedizin Berlin
    Full Title: Effect of IV iron (ferric carboxymaltose, Ferinject) on exercise tolerance, symptoms and quality of life in patients with heart failure with preserved ejection fraction (HFpEF) and iron deficiency ...
    Medical condition: Patients with heart failure with preserved ejection fraction (HFpEF) and iron deficiency (ID) with and without anaemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-004851-36 Sponsor Protocol Number: 404-201-00012 Start Date*: 2020-08-25
    Sponsor Name:Otsuka Pharmaceutical (OPDC)
    Full Title: Phase 3b, Randomized, Open-label, Active-controlled Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia ...
    Medical condition: Anemia of Chronic kidney disease (CKD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10002272 Anemia LLT
    21.0 100000004857 10076412 Chronic kidney disease stage 5 LLT
    21.0 100000004857 10076411 Chronic kidney disease stage 4 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002627-15 Sponsor Protocol Number: BAY94-8862/14564 Start Date*: 2013-05-27
    Sponsor Name:Bayer HealthCare AG
    Full Title: A randomized, double-blind, double-dummy, multi-center study to assess safety and efficacy of BAY 94-8862 in subjects with emergency presentation at the hospital because of worsening chronic heart ...
    Medical condition: Subjects with worsening chronic heart failure (WCHF) and left ventricular systolic dysfunction and either type 2 diabetes mellitus (DM type 2) with or without chronic kidney disease (CKD) or modera...
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004857 10064848 Chronic kidney disease LLT
    16.1 100000004861 10045242 Type II diabetes mellitus LLT
    16.1 100000004849 10066498 Cardiac failure chronic aggravated LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) AT (Completed) SE (Completed) LT (Completed) DE (Completed) HU (Completed) CZ (Completed) NO (Completed) NL (Completed) PT (Completed) DK (Completed) IT (Completed) ES (Completed) BG (Completed) GR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-001303-36 Sponsor Protocol Number: TRCA-303 Start Date*: 2018-11-07
    Sponsor Name:Tricida Inc.
    Full Title: A Phase 3b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of TRC101 in Delaying Chronic Kidney Disease Progression in Subjects with Metabolic Acidosis
    Medical condition: Chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BG (Prematurely Ended) GB (GB - no longer in EU/EEA) FR (Completed) SK (Completed) CZ (Completed) BE (Completed) ES (Prematurely Ended) PT (Completed) NL (Prematurely Ended) PL (Completed) IT (Prematurely Ended) RO (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-020965-26 Sponsor Protocol Number: VEG113387 Start Date*: 2010-10-28
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of pazopanib as adjuvant therapy for subjects with localized or locally advanced RCC following nep...
    Medical condition: Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038415 Renal cell carcinoma stage unspecified LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067946 Renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) DE (Completed) DK (Completed) IE (Completed) CZ (Completed) ES (Completed) BE (Completed) GR (Completed) GB (Completed) AT (Completed) PL (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-002349-23 Sponsor Protocol Number: 8232-CL-0004 Start Date*: 2015-01-26
    Sponsor Name:Astellas Pharma Europe BV (APEB)
    Full Title: A Phase 2, Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme inhibitor (ACEi) or Angiotensin Recep...
    Medical condition: Diabetic nephropathy
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) GB (Completed) HU (Completed) CZ (Completed) DE (Completed) BE (Completed) IT (Completed) NL (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-000871-17 Sponsor Protocol Number: AGS-003-007 Start Date*: 2013-09-02
    Sponsor Name:Argos Therapeutics, Inc.
    Full Title: An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)
    Medical condition: Renal cell carcinoma (RCC)
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038414 Renal cell carcinoma stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) CZ (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-002392-28 Sponsor Protocol Number: RM-493-Supplementation-Therapy Start Date*: 2014-11-28
    Sponsor Name:Charité Univeritaetsmedizin Berlin
    Full Title: Setmelanotide (RM-493) Treatment Trial in Patients with rare genetic disorders of obesity
    Medical condition: Body weight is regulated within the hypothalamus. In rare cases mutations in genes, which are embedded in the signaling cascades of the hypothalamus lead to early onset severe obesity. POMC is one ...
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-012198-36 Sponsor Protocol Number: NTx-RTx-LD-001 Start Date*: 2010-01-12
    Sponsor Name:Universitätsklinikum Giessen und Marburg - Standort Giessen
    Full Title: Einfluss von Rituximab-Induktion und Lebendspende auf Immunregulation und Viruskontrolle nach Nierentransplantation - eine prospektive Pilotstudie
    Medical condition: Living donor and deceased donor kidney transplantation. ABO compatible and ABO incompatible kidney transplantation.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-004314-17 Sponsor Protocol Number: CFTSp148 Start Date*: 2019-12-30
    Sponsor Name:The Christie NHS Foundation Trust
    Full Title: The CAPER study: A Phase Ib clinical trial of Cyclophosphamide And PEmbrolizumab in metastatic Renal cell carcinoma (CAPER Trial)
    Medical condition: Metastatic renal cell carcinoma with clear cell component
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10080007 Clear cell renal cell carcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 20 14:22:12 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA